Barrow Neurological Institute receives $5M for ibogaine study

Barrow Neurological Institute has been awarded a $5 million grant from the Arizona Department of Health Services to investigate the potential of ibogaine in treating neurological disorders, including traumatic brain injury (TBI). This funding supports a Phase 1/2 clinical trial, which will be conducted by a team of specialists in neurology, neurosurgery, and neuropsychiatry at Barrow, in collaboration with the Barrow Neuro Analytics Center and researchers from Arizona State University.

What the study aims to explore

The study will focus on ibogaine, a psychoactive alkaloid that has been gaining attention for its potential therapeutic applications. Known as a psychoplastogen and neuroplastogen, ibogaine is part of a group of psychedelic compounds being explored for their ability to promote neuroplasticity and potentially treat various neurological conditions.

Regulatory context

Ibogaine is among several psychedelic substances being re-evaluated for medical use globally. While it is not yet approved for medical use in the United States, research like this trial at Barrow Neurological Institute could contribute to a better understanding of its safety and efficacy, potentially influencing future regulatory decisions.

Why it matters

The research could provide significant insights into new treatment avenues for neurological disorders, which often have limited therapeutic options. If successful, the study could pave the way for larger clinical trials and eventual regulatory approval, offering hope to patients with conditions like TBI.

This initiative highlights the growing interest in psychedelic compounds as potential treatments for complex neurological issues.